Multiple Sclerosis Journal · 2015 · 41 citations · 15 references
Life SciencesImmunologyInfectious DiseasesAutoimmunityImmunopathologyImmunotherapyAntiviral TherapyMonoclonal Antibody TherapyMultiple SclerosisSeroprevalence StudiesLongitudinal SeroprevalenceMultiple Sclerosis AssociationsMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis ImmunopathologyMultiple Sclerosis TherapyPaired T-testSerial SeroconversionSeroconversion Rates
BACKGROUND: Anti-JC virus antibody status is a risk factor for progressive multifocal leukoencephalopathy after natalizumab treatment in multiple sclerosis. Previous studies have used a cross-sectional approach to conclude that the presence and duration of natalizumab treatment does not influence anti-JCV Ab seropositivity. OBJECTIVES: Using a longitudinal approach, we measured change in anti-JCV Ab results after natalizumab treatment. METHODS: Anti-JCV Ab results (n = 1154) from the second-generation STRATIFY JCV™ DxSelect™ test were analysed from an observational cohort of MS patients on natalizumab (n = 485; n = 340 with repeat testing; n = 657 repeat tests on natalizumab). RESULTS: Across sequential paired tests, seroconversion rate was greater than seroreversion rate (40/364 (11.0%) versus 18/293 (6.1%); p < 0.05). Moreover, anti-JCV Ab index increased across longitudinal paired tests (mA-B 0.102; paired t(656) = 5.0; p < 0.0001). This magnitude of Ab level increase far exceeds that expected due to increasing age alone. CONCLUSION: Our data suggest that natalizumab therapy is associated with a significant and substantial increase in anti-JCV Ab index over time. Further work should focus on the underlying mechanisms of this phenomenon, and the clinical relevance to risk stratification.
15
Tatiana Plavina, Meena Subramanyam, Gary Bloomgren et al. · Annals of Neurology · 2014 · 438 citations · Full text
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
Yiping Chen, Evelyn Bord, Troy Tompkins et al. · New England Journal of Medicine · 2009 · 211 citations · Full text